Apostolos Perelas1, Jessica Glennie2, Karen van Kerkhove2, Manshi Li3, Rachel G Scheraga4, Mitchell A Olman4, Daniel A Culver2. 1. Respiratory Institute, Cleveland Clinic Foundation, Cleveland, OH, USA. Electronic address: a_perelas@hotmail.com. 2. Respiratory Institute, Cleveland Clinic Foundation, Cleveland, OH, USA. 3. Quantitative Health Sciences Department, Cleveland Clinic Foundation, Cleveland, OH, USA. 4. Respiratory Institute, Cleveland Clinic Foundation, Cleveland, OH, USA; Department of Inflammation and Immunity, Lerner Research Institute, Cleveland, OH, USA.
Abstract
PURPOSE: Although safety and tolerability of approved antifibrotics has been reported extensively, little is known about their effects on weight. We analyzed predictors of weight change after one year of uninterrupted antifibrotic therapy in patients followed at our institution's interstitial lung disease clinic. METHODS/ RESULTS: We identified 80 patients on antifibrotic therapy (44 pirfenidone/36 nintedanib) with at least one year of follow-up and no therapy interruptions. Thirty-five patients (44%) lost more than 5% of their baseline body weight, and 11 (19%) lost more than 10%. A higher proportion of patients on nintedanib experienced a clinically significant weight loss (>5%) versus pirfenidone (61% vs 30%, p = 0.005). Univariate and multivariate analyses identified nintedanib therapy and a higher composite physiologic index (CPI) as predictors of weight loss. CONCLUSIONS: Weight loss is common among IPF patients on antifibrotic therapy. Nintedanib therapy and more advanced disease were identified as predictors of weight loss in this population.
PURPOSE: Although safety and tolerability of approved antifibrotics has been reported extensively, little is known about their effects on weight. We analyzed predictors of weight change after one year of uninterrupted antifibrotic therapy in patients followed at our institution's interstitial lung disease clinic. METHODS/ RESULTS: We identified 80 patients on antifibrotic therapy (44 pirfenidone/36 nintedanib) with at least one year of follow-up and no therapy interruptions. Thirty-five patients (44%) lost more than 5% of their baseline body weight, and 11 (19%) lost more than 10%. A higher proportion of patients on nintedanib experienced a clinically significant weight loss (>5%) versus pirfenidone (61% vs 30%, p = 0.005). Univariate and multivariate analyses identified nintedanib therapy and a higher composite physiologic index (CPI) as predictors of weight loss. CONCLUSIONS:Weight loss is common among IPFpatients on antifibrotic therapy. Nintedanib therapy and more advanced disease were identified as predictors of weight loss in this population.
Authors: Athol U Wells; Sujal R Desai; Michael B Rubens; Nicole S L Goh; Derek Cramer; Andrew G Nicholson; Thomas V Colby; Roland M du Bois; David M Hansell Journal: Am J Respir Crit Care Med Date: 2003-04-01 Impact factor: 21.405
Authors: Francesco Bonella; Michael Kreuter; Lars Hagmeyer; Claus Neurohr; Claus Keller; Martin J Kohlhaeufl; Joachim Müller-Quernheim; Katrin Milger; Antje Prasse Journal: Respiration Date: 2016-08-20 Impact factor: 3.580
Authors: Brett Ley; Christopher J Ryerson; Eric Vittinghoff; Jay H Ryu; Sara Tomassetti; Joyce S Lee; Venerino Poletti; Matteo Buccioli; Brett M Elicker; Kirk D Jones; Talmadge E King; Harold R Collard Journal: Ann Intern Med Date: 2012-05-15 Impact factor: 25.391
Authors: Talmadge E King; Williamson Z Bradford; Socorro Castro-Bernardini; Elizabeth A Fagan; Ian Glaspole; Marilyn K Glassberg; Eduard Gorina; Peter M Hopkins; David Kardatzke; Lisa Lancaster; David J Lederer; Steven D Nathan; Carlos A Pereira; Steven A Sahn; Robert Sussman; Jeffrey J Swigris; Paul W Noble Journal: N Engl J Med Date: 2014-05-18 Impact factor: 91.245
Authors: Luca Richeldi; Roland M du Bois; Ganesh Raghu; Arata Azuma; Kevin K Brown; Ulrich Costabel; Vincent Cottin; Kevin R Flaherty; David M Hansell; Yoshikazu Inoue; Dong Soon Kim; Martin Kolb; Andrew G Nicholson; Paul W Noble; Moisés Selman; Hiroyuki Taniguchi; Michèle Brun; Florence Le Maulf; Mannaïg Girard; Susanne Stowasser; Rozsa Schlenker-Herceg; Bernd Disse; Harold R Collard Journal: N Engl J Med Date: 2014-05-18 Impact factor: 91.245
Authors: Emily Siu Clausen; Courtney Frankel; Scott M Palmer; Laurie D Snyder; Patrick J Smith Journal: J Heart Lung Transplant Date: 2018-07-29 Impact factor: 10.247